Last reviewed · How we verify

NCT03917784

Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes

Status unknown Phase 4 Last updated 17 April 2019
What this trial tests

Phase 4 trial testing Curcumin in PreDiabetes in 142 participants. Status unknown.

Timeline
25 February 2019
Primary endpoint
30 November 2019
28 February 2020

Quick facts

Lead sponsorHospital General de México Dr. Eduardo Liceaga
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment142
Start date25 February 2019
Primary completion30 November 2019
Estimated completion28 February 2020
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Hospital General de México Dr. Eduardo Liceaga

Who can join

Adults 18 to 60, any sex, with PreDiabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effects of oral supplementation with curcumin on the insulin sensitivity in subjects with prediabetes. The half of participants will receive curcumin and bioperine in combination, while the other half receive placebo.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study.
    Wu YL, Lin ZJ, Li CC, Lin X, et al · · 2023 · cited 243× · PMID 36864020 · DOI 10.1038/s41392-023-01333-7
  2. Nrf2: The Master and Captain of Beta Cell Fate.
    Baumel-Alterzon S, Katz LS, Brill G, Garcia-Ocaña A, et al · · 2021 · cited 81× · PMID 33243626 · DOI 10.1016/j.tem.2020.11.002
  3. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases.
    Kim MJ, Jeon JH. · · 2022 · cited 60× · PMID 35269986 · DOI 10.3390/ijms23052846
  4. Therapeutic Effect of Curcumin on Metabolic Diseases: Evidence from Clinical Studies.
    Zeng Y, Luo Y, Wang L, Zhang K, et al · · 2023 · cited 38× · PMID 36834734 · DOI 10.3390/ijms24043323
  5. Pharmacological effects, formulations, and clinical research progress of curcumin.
    Hao M, Zhang C, Wang T, Hu H. · · 2025 · cited 9× · PMID 40166470 · DOI 10.3389/fphar.2025.1509045

Verify or expand the search:

Other trials of Curcumin

Trials testing the same drug.

Other recruiting trials for PreDiabetes

Currently open trials in the same condition.

Other Hospital General de México Dr. Eduardo Liceaga trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03917784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing